Leptomeningeal Disease Diagnosed Using CSF Cell-Free DNA
By LabMedica International staff writers Posted on 26 Aug 2021 |
Image: Small round blue tumor cells found in the CSF of a patient with leptomeningeal disease from rhabdomyosarcoma (Photo courtesy of Pediatric Oncology)
Leptomeningeal disease (LMD) is a devastating complication of solid and liquid systemic and central nervous system malignant neoplasms. LMD, in which cancer metastasizes to the cerebrospinal fluid, occurs in 4% to 15% of cancer patients and is associated with poor survival, with untreated patients dying within four to six weeks.
Leptomeningeal disease is typically diagnosed via identification of malignant cells in cerebrospinal fluid (CSF), most commonly obtained via lumbar puncture or ventriculoperitoneal (VP) shunt access. CSF cytological analysis. The currently most reliable diagnostic method, has a sensitivity of approximately only 75% and is known to produce persistently negative results in approximately 10% of patients.
A large team of Neuro-oncologists at the Massachusetts General Hospital (Boston, MA, USA) and their colleagues conducted a diagnostic study to assess the use of genomic sequencing of CSF samples obtained from 30 patients with suspected or confirmed LMD from 2015 through 2018 to identify tumor-derived cfDNA. This study consisted of two patient populations: 22 patients with cytologically confirmed LMD without parenchymal tumors abutting their CSF and eight patients with parenchymal brain metastases with no evidence of LMD.
Cell-free DNA was isolated from blood plasma and CSF using a QIASymphony instrument with the QIASymphony DSP Circulating DNA Kit (Qiagen, Hilden, Germany). A subset of libraries was prepared with unique molecular identifier adapters (Integrated DNA Technologies, Coralville, IA, USA). Prepared libraries were sequenced on HiSeq X, HiSeq 2500, or HiSeq 4000 instruments (Illumina, San Diego, CA, USA) to a targeted mean depth of 0.1X. Samples were aligned to hg19 using bwa-mem, version 0.7.7-r441.
The scientists reported that in total, 30 patients (23 women [77%]; median age, 51 years [range, 28-81 years]), primarily presenting with metastatic solid malignant neoplasms, participated in this study. For 48 follow-up samples from patients previously diagnosed via cytological analysis as having LMD with no parenchymal tumor abutting CSF, cfDNA findings were accurate in the assessment of LMD in 45 samples, whereas cytological analysis was accurate in only 36 samples. Of 43 LMD-positive samples, CSF cfDNA analysis was sensitive to LMD in 40 samples and cytological analysis was sensitive to LMD in 31 samples, a significant difference. For three patients with parenchymal brain metastases abutting the CSF and no suspicion of LMD, cytological findings were negative for LMD in all three patients, whereas cfDNA findings were positive in all three patients.
Priscilla K. Brastianos, MD, Assistant Professor of Medicine and a co-senior author of the study, said, “If we are able to confidently diagnose LMD using cell-free DNA earlier and with fewer invasive procedures, then we can institute treatment sooner and enroll patients in clinical trials for new LMD treatments. The ultimate hope is that we can improve patient survival with earlier diagnosis and treatment for this deadly disease.”
The authors concluded that the diagnostic study found improved sensitivity and accuracy of cfDNA CSF testing versus cytological assessment for diagnosing LMD with the exception of parenchymal tumors abutting CSF, suggesting improved ability to diagnosis LMD. The study was published on August 9, 2021 in the journal JAMA Network Open.
Related Links:
Massachusetts General Hospital
Qiagen
Integrated DNA Technologies
Illumina
Leptomeningeal disease is typically diagnosed via identification of malignant cells in cerebrospinal fluid (CSF), most commonly obtained via lumbar puncture or ventriculoperitoneal (VP) shunt access. CSF cytological analysis. The currently most reliable diagnostic method, has a sensitivity of approximately only 75% and is known to produce persistently negative results in approximately 10% of patients.
A large team of Neuro-oncologists at the Massachusetts General Hospital (Boston, MA, USA) and their colleagues conducted a diagnostic study to assess the use of genomic sequencing of CSF samples obtained from 30 patients with suspected or confirmed LMD from 2015 through 2018 to identify tumor-derived cfDNA. This study consisted of two patient populations: 22 patients with cytologically confirmed LMD without parenchymal tumors abutting their CSF and eight patients with parenchymal brain metastases with no evidence of LMD.
Cell-free DNA was isolated from blood plasma and CSF using a QIASymphony instrument with the QIASymphony DSP Circulating DNA Kit (Qiagen, Hilden, Germany). A subset of libraries was prepared with unique molecular identifier adapters (Integrated DNA Technologies, Coralville, IA, USA). Prepared libraries were sequenced on HiSeq X, HiSeq 2500, or HiSeq 4000 instruments (Illumina, San Diego, CA, USA) to a targeted mean depth of 0.1X. Samples were aligned to hg19 using bwa-mem, version 0.7.7-r441.
The scientists reported that in total, 30 patients (23 women [77%]; median age, 51 years [range, 28-81 years]), primarily presenting with metastatic solid malignant neoplasms, participated in this study. For 48 follow-up samples from patients previously diagnosed via cytological analysis as having LMD with no parenchymal tumor abutting CSF, cfDNA findings were accurate in the assessment of LMD in 45 samples, whereas cytological analysis was accurate in only 36 samples. Of 43 LMD-positive samples, CSF cfDNA analysis was sensitive to LMD in 40 samples and cytological analysis was sensitive to LMD in 31 samples, a significant difference. For three patients with parenchymal brain metastases abutting the CSF and no suspicion of LMD, cytological findings were negative for LMD in all three patients, whereas cfDNA findings were positive in all three patients.
Priscilla K. Brastianos, MD, Assistant Professor of Medicine and a co-senior author of the study, said, “If we are able to confidently diagnose LMD using cell-free DNA earlier and with fewer invasive procedures, then we can institute treatment sooner and enroll patients in clinical trials for new LMD treatments. The ultimate hope is that we can improve patient survival with earlier diagnosis and treatment for this deadly disease.”
The authors concluded that the diagnostic study found improved sensitivity and accuracy of cfDNA CSF testing versus cytological assessment for diagnosing LMD with the exception of parenchymal tumors abutting CSF, suggesting improved ability to diagnosis LMD. The study was published on August 9, 2021 in the journal JAMA Network Open.
Related Links:
Massachusetts General Hospital
Qiagen
Integrated DNA Technologies
Illumina
Latest Pathology News
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy
- Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes